Duality Biotherapeutics, Inc. (HKG:9606)

Market Cap	26.25B
Revenue (ttm)	2.38B +8.7%
Net Income	-3.10B
EPS	-124.82
Shares Out	90.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,844,058
Average Volume	610,446
Open	291.20
Previous Close	291.20
Day's Range	281.20 - 325.20
52-Week Range	165.50 - 563.50
Beta	n/a
RSI	35.39
Earnings Date	Apr 2, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 191
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9606

Financial Performance

Financial numbers in CNY